ADDvise Q3 2023: Lab sales above expectations and solid margins - Redeye

Redeye provides its initial take on ADDvise’s Q3 2023 report, which came in broadly above our estimates. We judge that positives from the report include continued sales growth and margin expansion, especially in the company’s Lab segment. Notable negatives include weak cash conversion of c31%, explained by ADDvise’s organic growth leading to increased working capital.

Länk till analysen i sin helhet: https://www.redeye.se/research/950628/addvise-q3-2023-lab-sales-above-expectations-and-solid-margins?utm_source=finwire&utm_medium=RSS